For high-risk, PTEN-deficient metastatic prostate cancer, a proposed strategy to maximize benefit while minimizing toxicity is sequential intensification. Clinicians can administer a triplet of ADT, an ARPI, and docetaxel first, and only after the chemotherapy course is complete, add the AKT inhibitor capivasertib to avoid severe, overlapping toxicities.

Despite clinicians frequently administering docetaxel triplets to high-risk metastatic hormone-sensitive prostate cancer patients, no prospective trial supports docetaxel specifically in PTEN-deficient disease or proves chemotherapy triplets outperform ADT plus ARPI. Dr. Neeraj Agarwal emphasizes that capivasertib paired with abiraterone is backed by Level 1 prospective evidence from the CAPITELO-281 trial. Clinicians should follow evidence-based targeted regimens rather than unvalidated chemotherapy in this molecular subset.

The prevalence of PTEN loss is not static; it increases significantly as prostate cancer advances. While less common in localized disease, it can be found in up to 25% of patients with metastatic disease. This escalating frequency with disease progression underscores its role as a key driver of cancer advancement and a critical therapeutic target in later stages.

Oligometastatic prostate cancer accompanied by PTEN loss behaves aggressively and rapidly converts into polymetastatic disease or castration resistance. Dr. Neeraj Agarwal warns against being misled by low volume into using metastasis-directed radiation. Radiation trials lack large phase 3 confirmation and perform poorly in tumor suppressor gene mutations. Oncologists should proceed straight to aggressive systemic targeted therapy rather than wasting time arranging oligometastatic radiation.

The AKT pathway, activated by PTEN loss, drives cancer growth independently of the androgen receptor, which controls PSA production. This discordance means clinicians cannot rely on PSA alone and must use systematic imaging to detect progression in this specific patient subgroup.

PTEN loss is seen very early in prostate cancer development. However, its primary role is not initiating the cancer but rather accelerating its progression in grade, stage, and disease state. The initial driver is more often related to androgen receptor biology.

In the CAPITELO-281 trial, one-third of prostate cancer patients with PTEN deficiency demonstrated radiographic or clinical progression without meeting standard PSA progression criteria. Dr. Neeraj Agarwal stresses that clinicians should not rely on PSA monitoring alone in this cohort. Instead, oncologists must convince reluctant patients to undergo routine CT, bone, or PSMA PET scans to avoid catastrophic consequences like paraplegia from unmonitored spinal cord compression.

In patients with PTEN loss, cancer growth is driven by the PI3K-AKT pathway, which doesn't activate the PSA gene. This can lead to significant disease progression with a low or stable PSA, making PSA a poor surrogate for disease activity in this sub-population.

Patients with PTEN-deficient prostate cancer often experience significant clinical or radiographic disease progression without a correspondingly rapid or high rise in PSA levels. This biological characteristic makes PSA an unreliable marker, necessitating a proactive strategy of frequent imaging to detect progression and intervene in a timely manner.